Juniper Genomics

, trading under the name Juniper Genomics is a biotechnology company that specializes in enhancing in vitro fertilization (IVF) outcomes through innovative genomic technologies. Juniper Genomics specializes in advanced solutions for in vitro fertilization (IVF) through its proprietary technology that leverages whole genome and transcriptome sequencing alongside sophisticated data analysis. The company's core offerings center around enhancing embryo selection accuracy to ensure a higher likelihood of success for fertility treatments. By collecting extensive input data, including DNA, RNA, and parental information, Juniper Genomics processes and analyzes this data to create a rich dataset focused on IVF outcomes. This integration of data into a sophisticated algorithm enables clinicians to select the most viable embryo for transfer, significantly reducing the emotional and financial burden associated with IVF procedures.Juniper Genomics operates on a revenue model that includes partnerships with fertility clinics and direct services to patients undergoing IVF treatments. The company’s offerings focus on improving embryo viability through scientific validation in transaction structures that favor B2B engagements with reproductive health specialists. The service model involves one-time fees or subscription arrangements for ongoing analysis and support, providing clinics access to Juniper's technology. As these clinics integrate Juniper's solutions into their workflows, it bolsters their service offerings while potentially enhancing patient outcomes. The core product, which focuses on embryo selection based on robust genetic data, positions Juniper Genomics in the reproductive health market.

1. Seed

   Jun 26, 2025

   Amount

   $4.6M

   Investors

   Locked

2. Seed

   Nov 1, 2022

   Amount

   Undisclosed

   Investors

   Locked